Cost-effectiveness of human papillomavirus vaccination in Germany

Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Deleré Y, Ultsch B, Wichmann O, Krämer A, Greiner W (2017)
Cost Effectiveness and Resource Allocation 15(1): 18.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
OA 1.03 MB
Damm, OliverUniBi; Horn, Johannes; Mikolajczyk, Rafael T.; Kretzschmar, Mirjam E. E.; Kaufmann, Andreas M.; Deleré, Yvonne; Ultsch, Bernhard; Wichmann, Ole; Krämer, AlexanderUniBi ; Greiner, WolfgangUniBi
Abstract / Bemerkung
Background The aim of this study was to assess the cost-effectiveness of human papillomavirus (HPV) vaccination in addition to the current cervical cancer screening programme in Germany using a dynamic transmission model. Methods Based on a mathematical model simulating the transmission dynamics and the natural history of HPV infection and associated diseases (cervical intraepithelial neoplasia, cervical cancer, and genital warts), we estimated the epidemiological and economic consequences of HPV vaccination with both the quadrivalent and bivalent vaccines. In our base case analysis, we assessed the cost-effectiveness of vaccinating 12-year-old girls with a 3-dose schedule. In sensitivity analysis, we also evaluated the use of a 2-dose schedule and assessed the impact of vaccinating boys. Results From a health care payer perspective, incremental cost-effectiveness ratios (ICERs) of a 3-dose schedule were €34,249 per quality-adjusted life year (QALY) for the bivalent and €14,711 per QALY for the quadrivalent vaccine. Inclusion of indirect costs decreased ICERs by up to 40%. When adopting a health care payer perspective, ICERs of a 2-dose approach decreased to €19,450 per QALY for the bivalent and to €3645 per QALY for the quadrivalent vaccine. From a societal perspective, a 2-dose approach using the quadrivalent vaccine was a cost-saving strategy while using the bivalent vaccine resulted in an ICER of €13,248 per QALY. Irrespective of the perspective adopted, additional vaccination of boys resulted in ICERs exceeding €50,000 per QALY, except for scenarios with low coverage (20%) in girls. Conclusions Our model results suggest that routine HPV vaccination of 12-year-old girls with three doses is likely to be cost-effective in Germany. Due to the additional impact on genital warts, the quadrivalent vaccine appeared to be more cost-effective than the bivalent vaccine. A 2-dose schedule of the quadrivalent vaccine might even lead to cost savings when adopting a societal perspective. The cost-effectiveness of additional vaccination of boys was highly dependent on the coverage in girls.
HPV Vaccination Economic evaluation Cost-effectiveness Dynamic transmission model Germany
Cost Effectiveness and Resource Allocation
Open-Access-Publikationskosten wurden durch die Deutsche Forschungsgemeinschaft und die Universität Bielefeld gefördert.
Page URI


Damm O, Horn J, Mikolajczyk RT, et al. Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation. 2017;15(1): 18.
Damm, O., Horn, J., Mikolajczyk, R. T., Kretzschmar, M. E. E., Kaufmann, A. M., Deleré, Y., Ultsch, B., et al. (2017). Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation, 15(1), 18. doi:10.1186/s12962-017-0080-9
Damm, O., Horn, J., Mikolajczyk, R. T., Kretzschmar, M. E. E., Kaufmann, A. M., Deleré, Y., Ultsch, B., Wichmann, O., Krämer, A., and Greiner, W. (2017). Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation 15:18.
Damm, O., et al., 2017. Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation, 15(1): 18.
O. Damm, et al., “Cost-effectiveness of human papillomavirus vaccination in Germany”, Cost Effectiveness and Resource Allocation, vol. 15, 2017, : 18.
Damm, O., Horn, J., Mikolajczyk, R.T., Kretzschmar, M.E.E., Kaufmann, A.M., Deleré, Y., Ultsch, B., Wichmann, O., Krämer, A., Greiner, W.: Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation. 15, : 18 (2017).
Damm, Oliver, Horn, Johannes, Mikolajczyk, Rafael T., Kretzschmar, Mirjam E. E., Kaufmann, Andreas M., Deleré, Yvonne, Ultsch, Bernhard, Wichmann, Ole, Krämer, Alexander, and Greiner, Wolfgang. “Cost-effectiveness of human papillomavirus vaccination in Germany”. Cost Effectiveness and Resource Allocation 15.1 (2017): 18.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Copyright Statement:
Dieses Objekt ist durch das Urheberrecht und/oder verwandte Schutzrechte geschützt. [...]
Access Level
OA Open Access
Zuletzt Hochgeladen
MD5 Prüfsumme

5 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Pricing of HPV vaccines in European tender-based settings.
Qendri V, Bogaards JA, Berkhof J., Eur J Health Econ 20(2), 2019
PMID: 30051152
Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses.
Diaz M, de Sanjosé S, Bosch FX, Bruni L., Rep Pract Oncol Radiother 23(6), 2018
PMID: 30534011
Reply to When flawed modeling justifies cost-effectiveness: Making sense of "Band-Aid" modeling.
Prinja S, Jyani G, Bahuguna P, Faujdar DS, Kumar R., Cancer 124(15), 2018
PMID: 29750834
Background paper for the recommendation of HPV vaccination for boys in Germany.
Takla A, Wiese-Posselt M, Harder T, Meerpohl JJ, Röbl-Mathieu M, Terhardt M, van der Sande M, Wichmann O, Zepp F, Klug SJ., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 61(9), 2018
PMID: 30167729
Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.
Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG., Viruses 10(12), 2018
PMID: 30572620

89 References

Daten bereitgestellt von Europe PubMed Central.

The causal relation between human papillomavirus and cervical cancer.
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV., J. Clin. Pathol. 55(4), 2002
PMID: 11919208
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.
Gillison ML, Chaturvedi AK, Lowy DR., Cancer 113(10 Suppl), 2008
PMID: 18980286
Cancers attributable to human papillomavirus infection.
Grulich AE, Jin F, Conway EL, Stein AN, Hocking J., Sex Health 7(3), 2010
PMID: 20719211
Genital human papillomavirus infection.
Dunne EF, Markowitz LE., Clin. Infect. Dis. 43(5), 2006
PMID: 16886157
The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis.
Delere Y, Wichmann O, Klug SJ, van der Sande M, Terhardt M, Zepp F, Harder T., Dtsch Arztebl Int 111(35-36), 2014
PMID: 25249360
Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus.
Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK., J Clin Med 4(4), 2015
PMID: 26239350
Against which human papillomavirus types shall we vaccinate and screen? The international perspective.
Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ., Int. J. Cancer 111(2), 2004
PMID: 15197783
Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts.
Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R., J. Clin. Microbiol. 33(8), 1995
PMID: 7559948
Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2014
Wissenschaftliche Begründung für die Änderung der Empfehlung zur Impfung gegen humane Papillomviren
Estimating the long-term effects of HPV vaccination in Germany.
Horn J, Damm O, Kretzschmar ME, Delere Y, Wichmann O, Kaufmann AM, Garbe E, Kramer A, Greiner W, Mikolajczyk RT., Vaccine 31(19), 2013
PMID: 23518405
Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom.
Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ., Vaccine 28(24), 2009
PMID: 19909831
Model for assessing human papillomavirus vaccination strategies.
Elbasha EH, Dasbach EJ, Insinga RP., Emerging Infect. Dis. 13(1), 2007
PMID: 17370513
Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria.
Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U., Vaccine 27(37), 2009
PMID: 19567244
The predicted effect of changes in cervical screening practice in the UK: results from a modelling study.
Canfell K, Barnabas R, Patnick J, Beral V., Br. J. Cancer 91(3), 2004
PMID: 15266332
A multi-type HPV transmission model.
Elbasha EH, Dasbach EJ, Insinga RP., Bull. Math. Biol. 70(8), 2008
PMID: 18841421
Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK.
Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M., Br. J. Cancer 96(1), 2006
PMID: 17146475
Long-term public health impact of vaccination against cervical cancer in Germany
Schneider A, Hammerschmidt T, Schwarz TF, Rogoza RM, Ferko N, Siebert U., 2007

Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry K, Krämer A, Siebert U., 2010
Re: Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections.
Mikolajczyk RT, Horn J, Damm O, Kaufmann AM, Kretzschmar ME., J. Natl. Cancer Inst. 104(2), 2012
PMID: 22232131
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.
Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA., J. Infect. Dis. 181(6), 2000
PMID: 10837170
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.
Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A; Costa Rican Vaccine Trial Group, Alfaro M, Barrantes M, Bratti MC, Cardenas F, Cortes B, Espinoza A, Estrada Y, Gonzalez P, Guillen D, Herrero R, Jimenez SE, Morales J, Morera LA, Perez E, Porras C, Rodriguez AC, Villegas M, Freer E, Bonilla J, Silva S, Atmella I, Ramirez M, Macklin N, Hildesheim A, Lowy DR, Schiffman M, Schiller JT, Sherman M, Solomon D, Wacholder S, Pinto L, Garcia-Pineres A, Eklund C, Hutchinson M, Quint W, van Doorn LJ, Bougelet C., J. Natl. Cancer Inst. 102(21), 2010
PMID: 20944077

Kerek-Bodden H, Altenhofen L, Brenner G., 2009

[HPV vaccination coverage in German girls: results of the KiGGS study: first follow-up (KiGGS Wave 1)].
Poethko-Muller C, Buttmann-Schweiger N; KiGGS Study Group., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57(7), 2014
PMID: 24950836
Erste Erfahrungen zur Akzeptanz der HPV-Impfung
Roggendorf H., 2009
Human papillomavirus vaccine uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010.
Stocker P, Dehnert M, Schuster M, Wichmann O, Delere Y., Hum Vaccin Immunother 9(1), 2012
PMID: 22995838
Long-term efficacy and safety of human papillomavirus vaccination.
De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G., Int J Womens Health 6(), 2014
PMID: 25587221
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P., Gynecol. Oncol. 115(3 Suppl), 2009
PMID: 19217149
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.
Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA., Vaccine 25(21), 2007
PMID: 17445955
Therapiefortschritte beim primären Zervixkarzinom
Beckmann MW, Mehlkorn G, Thiel F, Breuel C, Fasching PA, Ackermann S., 2005
Stadienbezogene Therapie des Zervixkarzinoms
Dannecker C, Hantschmann P, Friese K., 2008


Hillemanns P., 2004

Cost of screening and treatment of cervical dyskaryosis in Germany.
Petry KU, Breugelmans JG, Benard S, Lamure E, Littlewood KJ, Hillemanns P., Eur. J. Gynaecol. Oncol. 29(4), 2008
PMID: 18714567
Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study.
Hillemanns P, Breugelmans JG, Gieseking F, Benard S, Lamure E, Littlewood KJ, Petry KU., BMC Infect. Dis. 8(), 2008
PMID: 18518976



The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
Brisson M, Van de Velde N, De Wals P, Boily MC., Vaccine 25(29), 2007
PMID: 17561316
Abnormal outcomes following cervical cancer screening: event duration and health utility loss.
Insinga RP, Glass AG, Myers ER, Rush BB., Med Decis Making 27(4), 2007
PMID: 17585005


German recommendations on health economic evaluation: third and updated version of the Hanover Consensus.
Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C; Hanover Consensus Group, Adam H, Jurgen Ahrens H, Boehnke A, Breyer F, Cassel D, Doerner R, Felder S, Flessa S, Frick M, Goertz A, Hansen L, Happich M, Haeussler B, Hebel D, Henke KD, Hessel F, Hilf C, Jaecker A, Jacobs K, Kailuweit I, Kifmann M, Knappe E, Kohlmann T, Koenig HH, Kraemer W, Leu RE, Marhoefer M, Meidenbauer T, Merkesdal S, Mueller R, Mueller U, Munte A, Neubauer G, Oberender P, Osowski U, Peter J, Raffelhueschen B, Rauner K, Resch A, Ried W, Ruether A, Runge C, Rychlik R, Schmeinck W, Schnorpfeil W, Schulte G, Schultes HJ, Schulze-Solce HN, Scriba P, Selbmann HK, Siebert U, Spiro TC, Ulrich V, Voecking J, Werner I, Wille E, Willich SN, Yzer C., Value Health 11(4), 2008
PMID: 18194408
Health economic evaluation of vaccines
Damm O, Ultsch B., 2015
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E., JAMA 309(17), 2013
PMID: 23632723
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial Study Group Authors, Gonzalez P, Jimenez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors, Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group, Garland SM, Mindel A, Skinner SR, De Sutter P, Poppe WA, Tjalma WA, De Carvalho NS, Naud P, Teixeira JC, Aoki FY, Diaz-Mitoma F, Ferguson L, Miller M, Papp K, Ramjattan B, Romanowski B, Orr PH, Apter D, Karppa T, Kudjoi N, Lehtinen M, Lonnberg K, Palmroth J, Paavonen J, Petaja T, Tuomivaara L, Gent T, Grubert T, Hopker WD, Peters K, Schulze K, Schwarz TF, Waddell R, Salmeron J, Crisostomo C, Del Rosario-Raymundo MR, Raymundo JE, Germar MJ, Limson G, Villanueva G, Zamora JD, Bajo-Arenas J, Bayas J, Campins M, Castellsague X, Castro M, Centeno C, Rodriguez de la Pinta ML, Torne A, Vidart JA, Chow SN, Yu MH, Cruickshank M, Hakim EA, Lewis D, Szarewski A, Ackerman R, Caldwell M, Chambers C, Chatterjee A, DeMars L, Fine P, Huh W, Klein T, Lalezari J, Leeman L, Luber S, Martens M, Peterson C, Rosen J, Seidman L, Sperling R, Stager M, Stapleton J, Waldbaum A, Wheeler CM, Colau B, Genevrois S, Martens N, Houard N, Poncelet S, Provenzano C, Tonglet A, Van Hoof C, Descamps D, Hardt K, Xhenseval V, Zahaf T, Alt E, Iskaros B, Limaye A, Luff RD, McNeeley M, Winkler B, Molijn A, Quint W, Struijk L, Van de Sandt M, Van Doorn LJ, Klugman KP, Nieminen P, Bergeron C, Eisenstein E, Karron R, Marks R, Nolan T, Tay SK., Lancet Oncol. 16(7), 2015
PMID: 26071347
Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.
Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, Suryakiran P, Thomas F, Struyf F., Hum Vaccin Immunother 10(5), 2014
PMID: 24576907
Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States.
Forhan SE, Gottlieb SL, Sternberg MR, Xu F, Datta SD, McQuillan GM, Berman SM, Markowitz LE., Pediatrics 124(6), 2009
PMID: 19933728
Prevalence of human papillomavirus types in women screened by cytology in Germany.
Klug SJ, Hukelmann M, Hollwitz B, Duzenli N, Schopp B, Petry KU, Iftner T., J. Med. Virol. 79(5), 2007
PMID: 17385693
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.
de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX., Lancet Infect Dis 7(7), 2007
PMID: 17597569
Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy.
Schneider A, Hoyer H, Lotz B, Leistritza S, Kuhne-Heid R, Nindl I, Muller B, Haerting J, Durst M., Int. J. Cancer 89(6), 2000
PMID: 11102899
Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort.
Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, Desai M., Br. J. Cancer 91(5), 2004
PMID: 15292939

HPV and cervical cancer in the 2007 report.
WHO/ICO Information Centre on HPV and Cervical Cancer., Vaccine 25 Suppl 3(), 2007
PMID: 18068032
Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.
Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S; IARC HPV Prevalence Surveys Study Group., Lancet 366(9490), 2005
PMID: 16168781
Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer.
Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM., Cancer Epidemiol. Biomarkers Prev. 14(5), 2005
PMID: 15894666
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM., Int. J. Cancer 121(3), 2007
PMID: 17405118
The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity.
Soergel P, Makowski L, Schippert C, Staboulidou I, Hille U, Hillemanns P., Hum Vaccin Immunother 8(2), 2012
PMID: 22426367
Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany
Hillemanns P, Petry KU, Largeron N, McAllister R, Tolley K, Büsch K., 2009
Cost-benefit analyses in the health-care literature: don't judge a study by its label.
Zarnke KB, Levine MA, O'Brien BJ., J Clin Epidemiol 50(7), 1997
PMID: 9253393
Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men.
Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ, Sonnenberg P, Gilson R, Bains I, Choi YH, Tanton C, Soldan K, Jit M., Clin. Infect. Dis. 64(5), 2017
PMID: 28011615
Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.
Ultsch B, Damm O, Beutels P, Bilcke J, Bruggenjurgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O., Pharmacoeconomics 34(3), 2016
PMID: 26477039
Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
de Kok IM, Habbema JD, van Rosmalen J, van Ballegooijen M., Eur. J. Cancer 47(3), 2011
PMID: 20971633
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.
Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De Carvalho NS, Castro-Sanchez M, Castellsague X, Poppe WA, De Sutter P, Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA, Bajo-Arenas J, Harper DM, Torne A, David MP, Struyf F, Lehtinen M, Dubin G., J. Infect. Dis. 208(9), 2013
PMID: 24092907
Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme.
Luyten A, Buttmann-Schweiger N, Luyten K, Mauritz C, Reinecke-Luthge A, Pietralla M, Meijer CJ, Petry KU., Int. J. Cancer 135(6), 2014
PMID: 24519782
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group, Denham I, Garland S, Mindel A, O'Sullivan M, Skinner SR, Waddell R, de Carvalho N, Naud P, Teixeira JC, De Sutter P, Poppe WA, Tjalma W, Aoki FY, Diaz-Mitoma F, Dionne M, Ferguson L, Miller M, Papp K, Ramjattan B, Romanowski B, Somani R, Apter D, Astikainen S, Karppa T, Kekki M, Keranen H, Kudjoi N, Kuortti M, Kupari M, Kyha-Osterlund L, Isaksson R, Lehtinen M, Levanen H, Liljamo T, Loonberg K, Niemi L, Paavonen J, Palmroth J, Petaja T, Rekonen S, Romppanen U, Siitari-Mattila M, Tuomivaara L, Vilkki M, Belling KH, Gent T, Grubert T, Harlfinger W, Holst A, Hopker WD, Jensen-El Tobgui S, Merder G, Peters K, Schoenian S, Schulze K, Schwarz T, Wackernagel C, Boselli F, Mojana G, Salmeron J, Benitez G, Crisostomo C, Del Rosario-Raymundo R, Germar MJ, Limson G, Raymundo J, Remollino MC, Villanueva G, Villanueva S, Zamora JD, Zamora L, Bajo J, Bayas J, Campins M, Castellsague X, Castro M, Centeno C, Cruzet F, Rodriguez L, Torne A, Vidart JA, Chow SN, Yu MH, Yuan CC, Huang SC, Ho HN, Chen RJ, Lin HH, Chu TY, Angsuwathana S, Jaisamrarn U, Wilawan K, Abdulhakim E, Cruickshank M, Kitchener H, Lewis D, Pavel I, Robinson J, Szarewski A, Ackerman R, Ault K, Bennett N, Caldwell M, Chambers C, Chatterjee A, Civitarese L, Demars L, De Santis T, Downs L, Ferris D, Fine P, Gall S, Harper D, Hedrick J, Herzig W, Hiraoka M, Huh W, Kamemoto L, Klein T, Koltun W, Kong A, Lalezari J, Lee P, Leeman L, Luber S, Martens M, Michelson J, Nebel W, Peterson C, Pitts K, Rosen J, Rosenfeld W, Scutella M, Seidman L, Sperling M, Sperling R, Stager M, Stapleton J, Swenson K, Thoming C, Twiggs L, Waldbaum A, Wheeler CM, Yardley M, Zbella E, Kiviat N, Klugman KP, Nieminen P, Bergeron C, Eisenstein E, Karron R, Marks R, Nolan T, Tay SK, Albers S, Bollaerts P, Camier A, Colau B, De Breyne A, Genevrois S, Issaka Z, Martens N, Peeters P, Smoes N, Spiessens B, Tavares F, Tonglet A, Vanden-Dunghen S, Vilain AS, Ward KR, Alt E, Iskaros B, Limaye A, Liu-Jarin X, Luff RD, McNeeley M, Provenzano C, Winkler B, Molijn A, Quint W, Struijk L, Van de Sandt M, Van Doorn LJ, Greenacre M, Baronikova S, Zahaf T, David MP, Declerck L, Dupin J, Maroye JL., Lancet 374(9686), 2009
PMID: 19586656
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators., N. Engl. J. Med. 356(19), 2007
PMID: 17494926
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D., N. Engl. J. Med. 364(5), 2011
PMID: 21288094
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E., J. Infect. Dis. 199(7), 2009
PMID: 19236279
HPV vaccine: Cervarix.
Szarewski A., Expert Opin Biol Ther 10(3), 2010
PMID: 20132062
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E., J. Natl. Cancer Inst. 96(8), 2004
PMID: 15100338
Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM, van Ballegooijen M, Habbema JD., J. Natl. Cancer Inst. 101(15), 2009
PMID: 19571256


Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®


PMID: 28878573
PubMed | Europe PMC

Suchen in

Google Scholar